GITNUX MARKETDATA REPORT 2024
Rituximab Side Effects Duration Statistics
The duration of side effects from Rituximab can vary widely but most commonly last for a few hours to a few days after infusion.
In the following post, we will explore the duration and impact of various side effects associated with rituximab treatment. From fatigue and infusion-related reactions to musculoskeletal pain and gastrointestinal symptoms, we will delve into the statistics surrounding these common adverse effects and their potential duration post-infusion. Stay tuned to learn more about the potential side effects of rituximab and how they may impact patients undergoing this treatment.
Statistic 1
"Up to 37% of patients might experience fatigue as a side effect, often lasting several days post-infusion."
Statistic 2
"The most common side effect of rituximab is infusion-related reactions, occurring in 29-50% of patients during the first infusion."
Statistic 3
"Up to 30% of rituximab-treated patients report experiencing chills during infusion."
Statistic 4
"Approximately 1% of patients on rituximab report experiencing cardiovascular events."
Statistic 5
"Rituximab-induced thyroid dysfunction most commonly presents as hypothyroidism in about 1-2% of cases."
Statistic 6
"Serious infusion-related reactions, mostly occurring within the first 30-120 minutes of the first infusion, impact around 10% of patients."
Statistic 7
"Musculoskeletal pain occurs in about 5-10% of patients receiving rituximab."
Statistic 8
"Mild to moderate skin rashes affect 10-15% of patients on rituximab, generally resolving within weeks."
Statistic 9
"B symptoms (fever, night sweats) associated with rituximab can persist for months, though often resolving with supportive care."
Statistic 10
"Late onset neutropenia can appear up to 48 weeks after rituximab administration in around 7% of patients."
Statistic 11
"Fever is reported in up to 40% of patients, often resolving within a few days post-infusion."
Statistic 12
"Rituximab can cause hypertension in roughly 4% of patients, typically resolving within hours post-infusion."
Statistic 13
"Most infusion-related side effects resolve within a few hours but some can last up to 24 hours."
Statistic 14
"Pancytopenia is a rare but serious side effect that has been reported in fewer than 1% of patients."
Statistic 15
"Gastrointestinal symptoms such as nausea and diarrhea occur in about 10-15% of rituximab-treated patients."
Statistic 16
"Immediate anaphylaxis due to rituximab is rare, occurring in less than 0.1% of cases."
Statistic 17
"Rituximab carries a risk of severe infections, particularly hepatitis B reactivation, observed in up to 3.5% of cases."
Statistic 18
"Rituximab-related infections occur in approximately 4–5% of cases."
Statistic 19
"Reactions decrease significantly with each subsequent infusion of rituximab."
Statistic 20
"The duration of hair loss caused by rituximab is highly variable and generally resolves after discontinuation."
Jannik Lindner
Can You Trust Our Report?
The statistics are checked by us and then entered into the database. Our market data reports have been linked to by some of the largest publishers and companies on the Internet.
